期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非典型抗精神病药物临床应用进展 被引量：11

Clinical application of atypical antipsychotics
下载PDF
导出
摘要 依据近年来国内外相关文献,对非典型抗精神病药物的作用机制、临床应用及药物不良反应进行综述。非典型抗精神病药物除了治疗精神分裂症外,还用于治疗心境障碍、边缘性人格障碍、强迫症、抽动-秽语综合征等精神障碍。研究较多的不良反应包括体重增加及血脂、血糖、催乳素水平升高等。 Atypical antipsychotics clinically manages schizophrenia as well as several affective disorders, such as mood disorder, border personality disorder, obsessive-compulsive neurosis and Tourette's syndrome. The common adverse reactions that the atypical antipsychotics cause include weight gain, hyperglycemia, hyperlipidemia and increment of prolactin secretion. This review summarized the mechanism, pharmacotherapeutics and safety of atypical antipsychotics.
作者 李焕德 原海燕
机构地区 中南大学湘雅二医院药剂科
出处 《中国新药杂志》 CAS CSCD 北大核心 2005年第5期540-544,共5页 Chinese Journal of New Drugs
关键词 非典型抗精神病药物 临床应用 药物不良反应 atypical antipsychotics clinical application side effect
分类号 R971.4 [医药卫生—药品] R749 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献41

  • 1Stahl SM. Introduction:what makes an antipsychotic atypical?[J]. J Clin Psychiatry, 1999,60(Suppl lO) : S3 - S4.
  • 2Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1 mechanism of action of atypical antipsychotics [ J ]. J Clin Psychiatry ,2001,62(10) :670 - 671.
  • 3Stahl SM. "Hit-and-run" actions at dopamine receptors,part 2 illustrating fast dissociation from dopamine receptors that typifies atypical antipsychoties[J].J Clin Psychiatry, 2001,62 (10) :747 - 748.
  • 4Stahl K,Steernan P.Dose fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis[J]. Am J Psychiatry ,2001,158(2) : 360 - 362.
  • 5Schmidt Aw, Lebel LA, Howard HR J r, et al. Zip rasidone:a nov-el antipsychotic agent with a unique human receptor binding profile[J]. Eur J Pharmacol,2001,425 (3) : 197 - 203.
  • 6Feldman PD, Kaiser CJ, Kennedy JS, et al. Comparison of risperidone and olartzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years[J]. J Clin Psychlatry,2003,64(9) :998 - 1004.
  • 7Bitter I,Dossenbaeh MR, Brook S, et al. Olartzapine versus cloza-pine in treatment-resistant or treatment-intolerant schizophrenia[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2004, 28(1):173- 178.
  • 8Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand [ J ]. Schizophr Res, 2003,61(2-3):303-307.
  • 9Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group [ J ].Int Clin Psychopharmacol, 2000,15 (3) : 121 - 128.
  • 10Hirsch SR,Kissling W,Bauml J ,et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia[J]. J Clln Psychiatry ,2002,63 (6) :516 - 520.

二级参考文献32

  • 1[1]Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapinc on positive symptoms in outpatients with schizophrenia [J].Am J Psychiatry,1994,151(1) :20 - 26.
  • 2[2]Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia[J ]. Am J Psychiatry, 1994,151 (6) :825 - 835.
  • 3[3]Millet D,NopoulosP. A comparative effectiveness study of risparidme and olanzapine in the treatment of schizophrenia[J ]. J Clin Psychiatry ,1999,60(10) :658 - 663.
  • 4[4]Tollef1son GD, Beasley CM, Tran PV, et al. Olanzapine verus haloperidol in the treatment of schizophrenia and schizoaffectiveand schizophreniform disorders: results of international collabrorative trial[J ]. Am J Psychiatry, 1997,154(4) :457 - 465.
  • 5[5]Coley RR, Tamminga CA, Bartbo J J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia[ J ]. Am J Psychiatry, 1998,155(6): 914 - 920.
  • 6[6]Arvanitis LA, Miller BG. Multiple fixed dose of Seroquel (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo [ J ]. Biol Psychiatry,1997,42(2) :233 - 246.
  • 7[7]Small JG, Hirsch SR, Arvantis LA, et al. Quetapine in patients with schizophrenia:a high and low-dose double-blind comparison with placebo[J]. Arch Gen Psychiatry, 1997,54(5) :549 - 557.
  • 8[8]Borison RL, Arvanitis LA, Miller BG, et al. An atypical antipsycbotic:efficacy and safety in a multicenter, placebo- controlledtrial in patients with schizophrenia[J]. J Clin Psychopharmacol,1996,16(2): 158 - 169.
  • 9[9]Pezawas L,Ouiner S, Moertl D, et al. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance[J ]. Int Clin Psychopha rmacol, 2000,15 (4): 207 - 214.
  • 10[10]Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120mg/day in the acute of schizophrenia and schizoaffective disorder:a 4-wek placebo-controlled trial[J ]. Psychopharmacology, 1998,14(2):173- 184.

共引文献19

同被引文献146

引证文献11

二级引证文献85

中国新药杂志
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部